Results 111 to 120 of about 29,994,236 (203)

Translational Barriers and AI‐Driven Challenges of Microfluidics‐Enabled Wearables and Implantable Systems in Personalized Medicine

Advanced Science, Volume 13, Issue 58, 19 October 2026.
An integrative review of microfluidics‐enabled wearables and implantable systems reveals a single‐track translation pipeline, bridging functional biomaterials with clinical utility. Dynamic feedback loops driven by artificial intelligence advance diagnostics toward personalized closed‐loop theranostics.
Ke Huang, Ching Yin Fong, Xin Huang, Bee Luan Khoo   +3 more
wiley   +1 more source

Noncanonical-NF-κB activation and DDX3 inhibition reduces the HIV-1 reservoir by elimination of latently infected cells ex-vivo

Microbiology Spectrum
Latency reversal and subsequent elimination of the human immunodeficiency virus-1 (HIV-1) reservoir using a combination of compounds with different mechanisms of action are considered a promising tool for HIV-1 cure.
Jade Jansen, Stefanie Kroeze, Shirley Man, Matteo Andreini, Jan-Willem Bakker, Claudio Zamperini, Alessia Tarditi, Neeltje A. Kootstra, Teunis B. H. Geijtenbeek   +8 more
doaj   +1 more source

Mucosal‐Associated Invariant T Cells in Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
The roles of MAIT cells in health and disease and their therapeutic applications. In healthy individuals, riboflavin metabolites secreted by commensal bacteria at mucosal sites are presented by MR1, leading to the activation of MAIT cells. Activated MAIT cells can maintain the barrier integrity of mucosal tissues in a steady state or migrate to the ...
Yu Zhao, Feng‐Mi Ou, Dan Liang, Yang Gao, Qing‐Qing Li, Yi‐Qun Kuang   +5 more
wiley   +1 more source

HIV-1 latency reversing agents converge on phosphoregulation of nuclear protein complexes

ABSTRACT Despite the success of antiretroviral therapy (ART), HIV-1 persists in latently infected cells, posing a central barrier to a cure. “Shock-and-kill” strategies using latency-reversing agents (LRAs) have shown some promise in reactivating viral gene expression ex vivo , but ...
Ni, Jocelyn J., Kaushal, Prashant, Sharma, Shipra, Makanani, Sara K., Delgado, Yennifer, Blanc, Sophie F., Olwal, Charles Ochieng, Ashley, Immy A., Winters, Declan M., Yang, Vivian, Phung, Callie N., Alba, Kareem, Wynn, Evan, Johnson, Jeffrey R., Hultquist, Judd F., Fregoso, Oliver I., Bouhaddou, Mehdi   +16 more
openaire   +2 more sources

HIV‐1 Vpr Drives a B Cell‐Like Phenotype in Primary CD4+ T Cells

MedComm, Volume 7, Issue 10, October 2026.
During acute HIV‐1 infection, Vpr induces transcriptional and epigenetic remodeling of primary CD4+ T cells, activating a transient B cell‐like program characterized by CD19, MS4A1, CD22, and PAX5 expression and increased chromatin accessibility at lymphocyte differentiation genes.
Peipei Wang, Jieying Li, Wei Wang, Zhuoyue Meng, Huixin Wu, Shumin Du, Kai Deng, Jinfeng Cai   +7 more
wiley   +1 more source

Glutamine Metabolism in Health and Diseases

MedComm, Volume 7, Issue 10, October 2026.
Glutamine metabolism acts as a metabolic hub connecting cellular stress adaptation, immune regulation, and disease development. Through regulating energy production, biosynthesis, redox balance, and nitrogen metabolism, glutamine supports cellular homeostasis under physiological and pathological conditions.
Yi Ding, Fan Tong, Jing Zeng, Chun‐Ping Cui   +3 more
wiley   +1 more source

Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA

, 2011
BACKGROUND: Early initiation of combination antiretroviral therapy (ART) during primary HIV-1 infection may prevent the establishment of large viral reservoirs, possibly resulting in improved control of plasma viraemia rebound after ART cessation ...
Niederoest, B, Fischer, M., Battegay, Manuel, Günthard, Huldrych F, Fischer, M, Gianella, S., Weber, R, Vernazza, P, Cavassini, M., Gianella, S, Swiss HIV Cohort Study,, Bernasconi, E, Cavassini, M, Battegay, M., Vernazza, P., Joos, B., Rauch, A., Bernasconi, Enos, Weber, R., von Wyl, Viktor, Günthard, Huldrych F., Niederoest, B., Rauch, A, von Wyl, V., Hirschel, Bernard, Rauch, Andri, Joos, B, Günthard, H.F., Joos, Beda, Günthard, H F, Hirschel, B, Gianella, Sara, Niederoest, Barbara, Vernazza, Pietro, Battegay, M, Fischer, Marek, Weber, Rainer, von Wyl, V, Hirschel, B., Cavassini, Matthias, Bernasconi, E.   +40 more
core   +1 more source

Targeted bacteriophage T4 nanoparticles reverse HIV-1 latency in human T cell line models

iScience
Summary: A major barrier for HIV-1 eradication is the latent virus reservoir containing stably integrated and silent proviruses in CD4+ T cells. Targeted reactivation and removal of this latent reservoir is a potential strategy for HIV-1 cure, but ...
Himanshu Batra, Jingen Zhu, Swati Jain, Neeti Ananthaswamy, Marthandan Mahalingam, Pan Tao, Camille Lange, Shawn Hill, Chaojie Zhong, Mary F. Kearney, Haitao Hu, Frank Maldarelli, Venigalla B. Rao   +12 more
doaj   +1 more source

Enhancing HIV-1 latency reversal through regulating the elongating RNA Pol II pause-release by a small-molecule disruptor of PAF1C. [PDF]

Sci Adv, 2023
Soliman SHA, Cisneros WJ, Iwanaszko M, Aoi Y, Ganesan S, Walter M, Zeidner JM, Mishra RK, Kim EY, Wolinsky SM, Hultquist JF, Shilatifard A.   +11 more
europepmc   +1 more source

A Multi‐Scale Computational Framework for Anti‐Persister Tuberculosis Drug Discovery

Chemical Biology &Drug Design, Volume 108, Issue 4, October 2026.
This review presents an integrated QSAR–scaffold design–docking–MD framework for discovering anti‐persister tuberculosis agents active in dormant granuloma‐like conditions. By targeting Mtb bioenergetics and prioritising dual NDH‐2/cytochrome bd oxidase inhibition, the workflow advances rational design of candidates with higher resistance barriers ...
Said Moshawih, Anguraj Moulishankar, Chee Yan Choo, Khang Wen Goh, Chrismawan Ardianto, Azam Che Idris, Long Chiau Ming   +6 more
wiley   +1 more source